{{'2023-02-01T13:20:54Z' | dateFormatFilter}}
Novo Nordisk files annual report with the SEC
Read more
{{'2023-02-01T06:30:42Z' | dateFormatFilter}}
Novo Nordisk's sales increased by 26% in Danish kroner and by 16% at constant exchange rates to DKK 177.0 billion in 2022
Read more
{{'2022-11-22T05:31:25Z' | dateFormatFilter}}
Novo Nordisk invests DKK 5.4 bn Danish kroner in expansion of clinical manufacturing facilities in Bagsværd, Denmark
Read more
Progress towards zero environmental impact
Being respected for adding value to society
Ensure distinct core capabilities and evolve culture
Further raise the innovation-bar for diabetes treatment
Develop a leading portfolio of superior treatment solutions for obesity
Strengthen and progress the Rare disease pipeline
Establish presence in Other serious chronic diseases focusing on CVD, NASH and CKD
Strengthen Diabetes leadership - aim at global value market share of more than 1/3
More than 25 billion DKK in Obesity sales by 2025
Secure a sustained growth outlook for Rare disease
Deliver solid sales and operating profit growth:
Drive operational efficiencies across the value chain to enable
investments in future growth assets
Deliver free cash flow to enable attractive capital allocation to shareholders
Investors
Share price
{{priceData.date}} {{priceData.time}}